Benzinga | Nov 9, 2021 11:33AM EST

Barclays Maintains Underweight on Arcturus Therapeutics, Lowers Price Target to $31

Barclays analyst Gena Wang maintains Arcturus Therapeutics (NASDAQ:ARCT) with a Underweight and lowers the price target from $46 to $31.